吲达帕胺对高血压病人血浆内皮素-1的影响

目的　研究轻、中度原发性高血压病人的血浆内皮素 1(ET 1)的变化及其在原发性高血压发生及发展中的作用 ,评价吲达帕胺对轻、中度原发性高血压的降压疗效及对这类病人血浆ET 1水平的影响 ,探讨吲达帕胺对高血压的影响机制。方法　将 30例轻、中度原发高血压病人和 30例正常人的血浆采用放射免疫法测定血浆ET 1水平 ,对高血压病人给予吲达帕胺治疗 2周 ,并进行治疗前后对照研究。结果　高血压组治疗后血压明显下降 ,平均舒张压降低 9 8mmHg ,P <0 0 1,降压有效率为 6 0 %。高血压组治疗前血浆ET 1较正常组显着升高 ,平均升高 34 5 5 3pg/L ,P <0 0 0 1,治疗后ET 1水平显着下降 ,平均降低 35 5 5 0pg/L ,P <0 0 0 1。结论　原发性高血压病人血浆ET 1较正常人高 ,这类人群存在内皮细胞分泌活动的紊乱 ,是原发性高血压疾病发展的重要环节。吲达帕胺 (2 5mg/d)对轻、中度原发高血压病人降压疗效显著 ,同时可降低血浆ET 1水平 ,从而可抑制内素促进高血压进展的作用。

The effect of indapamide on plasma ET-1 patients with hypertension

Objective To research the change of ET-1 in patients with mild to moderate essential hypertension and the effect of this change on the development of essential hypertension,evaluate the effect of indapamide and its mechanism on essential hypertension.Methods Radioimmunoassay(RIA) was employed to measure plasma ET-1 in 30 patients with essential hypertension and 30 healthy persons as control.The results after 2 weeks treatment of indapamide for the patients were compared.Results The blood pressure of hypertensive patients dropped apparently(P<0.01).The effective rate was 60%.Plasma ET-1 in patients with hypertension was higher than that in normal controls,which decreased after 2 weeks of treatment of indapamide(P<0.001).Conclusion The level of plasma ET in patients with mild to moderate essential hypertension is higher than that in normal,which suggests that the change of ET in plasma in patients with primary hypertension plays an important role in the development of hypertension.Indapamide(2.5mg per day) has a remarkable efficacy on moderate primary hypertension by means of decreaseing ET-1 in plasma as well,which inhibits the development of primary hypertension.